Life Science Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Life Science Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cardiology
Second generation drug-eluting stent system challenges current gold standard
April 10th, 2007
While research shows that drug-eluting stents effectively reduce restenosis and revascularization compared to bare-metal stents, questions and controversy surrounding the safety and efficacy of drug-eluting stents continue to dominate discussions and headlines. A study presented at the American College of Cardiology’s Innovation in Intervention: i2 Summit surveys the safety and efficacy of the second generation Xience™V Everolimus Eluting Coronary Stent System (EES), compared to the current gold standard paclitaxel-eluting stent (PES), to determine if it offers similar or enhanced outcomes. Innovation in Intervention: i2 Summit is an annual meeting for practicing cardiovascular...
Source: Life Science Weekly (2007-04-10)
|
